Annexin A1, formyl peptide receptor, and NOX1 orchestrate epithelial repair

Giovanna Leoni, Emory University
Ashfaqul Alam, Emory University
Philipp A. Neumann, Emory University
David J Lambeth, Emory University
Guangjie Cheng, Emory University
James McCoy, Emory University
Roland S. Hilgarth, Emory University
Kousik Kundu, Emory University
Niren Murthy, Emory University
Dennis Kusters, Emory University

Only first 10 authors above; see publication for full author list.

Journal Title: Journal of Clinical Investigation
Volume: Volume 123, Number 1
Publisher: American Society for Clinical Investigation | 2013-01-02, Pages 443-454
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.1172/JCI65831
Permanent URL: http://pid.emory.edu/ark:/25593/cws7h

Final published version: http://dx.doi.org/10.1172%2FJCI65831

Copyright information:
© 2013, American Society for Clinical Investigation
Accessed December 29, 2023 5:51 PM EST
Annexin A1, formyl peptide receptor, and NOX1 orchestrate epithelial repair

Giovanna Leoni,1 Ashfaqul Alam,1 Philipp-Alexander Neumann,1,2 J. David Lambeth,3 Guangjie Cheng,4 James McCoy,3 Roland S. Hilgarth,1 Kousik Kundu,1 Niren Murthy,5 Dennis Kusters,6 Chris Reutelingsperger,6 Mauro Perretti,7 Charles A. Parkos,1 Andrew S. Neish,1 and Asma Nusrat1

1Epithelial Pathobiology and Mucosal Inflammation Research Unit, Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA. 2Department of General Surgery, University of Münster, Münster, Germany. 3Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA. 4Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine Birmingham, Birmingham, Alabama, USA. 5The Wallace H. Coulter Department of Biomedical Engineering and Parker H. Petit Institute of Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, Georgia, USA. 6Cardiovascular Research Institute Maastricht, Department of Biochemistry, Maastricht University, Maastricht, The Netherlands. 7William Harvey Research Institute, Barts and The London School of Medicine, London, United Kingdom.

N-formyl peptide receptors (FPRs) are critical regulators of host defense in phagocytes and are also expressed in epithelia. FPR signaling and function have been extensively studied in phagocytes, yet their functional biology in epithelia is poorly understood. We describe a novel intestinal epithelial FPR signaling pathway that is activated by an endogenous FPR ligand, annexin A1 (ANXA1), and its cleavage product Ac2-26, which mediate activation of ROS by an epithelial NADPH oxidase, NOX1. We show that epithelial cell migration was regulated by this signaling cascade through oxidative inactivation of the regulatory phosphatases PTEN and PTP-PEST, with consequent activation of focal adhesion kinase (FAK) and paxillin. In vivo studies using intestinal epithelial specific Nox1−/−IEC and Anxa1−/− mice demonstrated defects in intestinal mucosal wound repair, while systemic administration of ANXA1 promoted wound recovery in a NOX1-dependent fashion. Additionally, increased ANXA1 expression was observed in the intestinal epithelium and infiltrating leukocytes in the mucosa of ulcerative colitis patients compared with normal intestinal mucosa. Our findings delineate a novel epithelial FPR1/NOX1-dependent redox signaling pathway that promotes mucosal wound repair.

Introduction

The intestinal epithelium forms a selective barrier that separates luminal contents from underlying tissue compartments, thereby playing a pivotal role in regulating exposure of the mucosal immune system to luminal microorganisms and their products. Pathologic states associated with epithelial injury and ulceration result in compromised integrity of the epithelial barrier. Repair of epithelial discontinuities and ultimate restoration, termed restitution, involve induced and coordinated migration of epithelial cells (1). Restitution is stimulated by a cascade of pro-resolving mediators in the inflamed mucosa (2–8). An important pro-resolving mediator is the calcium-dependent phospholipid-binding protein annexin A1 (ANXA1). Previous studies have reported that ANXA1 induced in endotoxemia, peritonitis, and arthritis exerts anti-inflammatory properties by suppression of leukocyte activation and transmigration (9–12). Such anti-inflammatory properties of ANXA1 are mediated by autocrine and paracrine signaling of a 26-amino-acid ANXA1 N-terminus peptide, Ac2-26, that is released from the full-length protein through regulated proteolysis (2, 13–16).

The biological effects of ANXA1 and its cleavage product Ac2-26 peptide are mediated by formyl peptide receptors (FPRs) (2, 17, 18). In humans 3 FPRs (FPR1, FPR2, and FPR3) regulate innate inflammatory responses. Their function has been most extensively investigated in the context of leukocyte recruitment and activation, where FPRs promote cell motility (chemotaxis) and microbicidal respiratory burst (19, 20). Neutrophil FPR activation with the bacterial peptide fMLF (formyl-methionyl-leucyl phenylalanine) induces Rac2-dependent NADPH oxidase–2 (NOX2) activation and microbicidal levels of ROS generation, which in turn mediate host defense (21). Additionally, ROS generated by non-phagocyte NOX1 in epithelial cells mediates important signaling events, and its levels are up to 2 orders of magnitude lower than during phagocyte microbicidal burst (22). While leukocyte FPR function has been well studied, it was only recently appreciated that FPRs are also expressed in the intestinal epithelium, where NOX1 function has remained enigmatic.

In this report we use complementary in vitro and in vivo approaches to delineate a novel signaling pathway by which ANXA1 promotes intestinal epithelial migration through activation of FPR1-, Rac1-, and NOX1-dependent redox signaling, leading to the oxidative inactivation of regulatory phosphatases, with subsequent modification of focal adhesion proteins involved in regulating cell migration. Furthermore, we demonstrate a therapeutic effect of ANXA1 mediated by NOX1 in promoting intestinal epithelial cell (IEC) wound closure in vivo. These findings elucidate a novel pro-resolution function of ANXA1 in mucosal wound repair.

Results

ANXA1 promotes IEC wound closure and cell-matrix adhesion. We have previously reported that the endogenous FPR ligand ANXA1 promotes epithelial cell motility and wound closure, but the underlying mechanism remains poorly understood (23). During inflammation and epithelial wound healing, ANXA1 is cleaved, generating an active peptide, Ac2-26. While the full-length ANXA1 protein binds leukocyte FPR2, its cleavage peptide acti-
vates FPR1 at a physiological concentration (3–10 μM) as used in our previous studies (24, 25). Using a model intestinal epithelial cell line, SK-CO15, and a well-characterized in vitro scratch wound assay, we observed that exposure to the ANXA1 mimic peptide Ac2-26 (3 μM) enhanced wound closure in IECs compared with control cells (68.72% ± 1.03% vs. 35.79% ± 0.78% at 24 hours, P < 0.0001) (Figure 1, A and B). The specificity of Ac2-26–induced effects on wound closure was confirmed by the FPR1 receptor antagonist cyclosporin H (CsH) (26), which blocked the pro-migratory effects of Ac2-26. Similarly, the pan-FPR antagonist Boc2 (27) reversed the effects of Ac2-26 on wound closure (Supplemental Figure 2A; supplemental material available online with this article; doi:10.1172/JCI65831DS1). Boc2 is selective for FPR1 at a low concentration (1 μM), but this selectivity is lost when the concentration is higher. However, the peptide WR4, known to antagonize FPR2 and FPR3, did not influence Ac2-26–mediated wound closure (28). These findings suggest that the pro-restitution effects of Ac2-26 are not likely mediated by FPR2 and FPR3. To confirm the inhibitory effects of WR4 on FPR2 and FPR3 in IECs, we incubated cells with selective FPR2 and FPR3 agonists, MMK1 (29) and F2L (30, 31), respectively, and examined their influence on wound closure. As shown in Supplemental Figure 1, WR4 inhibited the effects of MMK1 and F2L on wound closure. These data support a role of FPR1 in mediating Ac2-26 effects on IEC wound closure. To determine the relevance of the in vitro results, we assessed intestinal epithelial wound recovery in AnxaI–null (Anxa1–/–) mice. We determined the rate of colonic wound closure in Anxa1–/– and control mice by generating defined mechanical colonic mucosal wounds using a mouse colonoscope equipped with biopsy forceps. Images captured from the wound sites were used to quantify wound restitution at days 2 and 4 after injury. Representative images of wounds in control mice (BALB/c) and Anxa1–/– are shown in Figure 1C. Mice lacking ANXA1 demonstrated a significant delay in wound healing at day 4 as indicated by 29.8% ± 0.9% wound closure compared with 75.3% ± 1.57% in control normal BALB/c mice (P = 0.023). Collectively, these in vitro and in vivo results are consistent with a major function of ANXA1 in promoting IEC wound closure. Regulated turnover of cell matrix adhesions plays an important role in promoting cell migration. Thus, to investigate the mechanisms by which ANXA1 promotes cell motility, we analyzed the influence of Ac2-26 on IEC-matrix adhesion. SK-CO15 adhesion assays were performed using surfaces coated with ECL Cell Attachment Matrix (Millipore). As shown in Figure 1D, 15 minutes’ exposure to Ac2-26 increased the number of adherent cells compared with control cells (38.6 ± 0.3 vs. 17.5 ± 0.2, P < 0.0001). We next explored potential signaling pathways to identify the mechanism by which Ac2-26 enhances IEC-matrix adhesion and cell migration. Tyrosine phosphorylation and activation of focal adhesion proteins paxillin (Pax) and focal adhesion kinase (FAK) regulate cell matrix adhesion turnover and cell migration (32, 33). Thus, we analyzed the tyrosine phosphorylation of FAK and Pax by immunoblotting and confocal microscopy. Indeed, immunoblot analysis demonstrated that migrating cells incubated with Ac2-26 had increased tyrosine phosphorylation of Pax (Y118, 2.4-fold) and FAK (Y861, 2.2-fold) (Figure 1E). These findings were corroborated by confocal microscopy. As shown in Figure 1F, increased Pax-pY118 and FAK-pY861 were observed in basal “punctate” structures corresponding to focal adhesions in migrating IECs exposed to Ac2-26, as compared with control IECs. The FAK-pY861 labeling was more prominent at the leading edge of migrating IECs. These results are consistent with increased cell-matrix adhesion/turnover and consequent IEC motility in cells exposed to Ac2-26. Nox1 is a major determinant of Ac2-26/FPR1–induced ROS in IECs. Recently, we reported that IEC migration stimulated by enteric commensal microbiota is linked to induction of ROS (34). Since FPR activation in phagocytes induces ROS, via activation of the NOX2 NADPH oxidase (21), we investigated whether Ac2-26 induces intracellular ROS generation in epithelial cells. IECs express NOX1 NADPH oxidase, a ROS-generating enzyme and paralog of leukocyte NOX2 (35). We first confirmed NOX1 expression in cells of the model IEC line SK-CO15 by RT-PCR (Supplemental Figure 4C). IEC exposure to Ac2-26 induced a rapid increase in fluorescence of a stable intracellular redox-sensitive dye, Hydroxyl Cy3, within 15 minutes, and this effect was inhibited with the FPR1 antagonist CsH (Figure 2A). Importantly, Ac2-26–induced ROS generation was abrogated in cells pretreated with pertussis toxin (Ptxs; Supplemental Figure 3), a known G1/Gs protein inhibitor (36). Pretreatment of stimulated IECs with a general NADPH oxidase inhibitor, diphenyleneiodonium chloride (DPI), and the ROS scavenger N-acetyl cysteine (NAC), but not the mitochondrial electron transport inhibitor rotenone, abrogated Ac2-26–induced ROS generation (Figure 2A). Interestingly, ROS generation was most prominent at the wound edge, and this effect was accentuated by 15 minutes exposure to Ac2-26 (Figure 2B), consistent with an analogous increase in active focal adhesion proteins in the vicinity of wounds (Figure 1F). Furthermore, preincubation with DPI inhibited wound healing in IECs treated with Ac2-26 (Figure 2C). Together, these data are consistent with a role of NADPH oxidase in mediating ROS generation and wound closure, downstream of FPR1 activation by Ac2-26. For further determination of the relevance of these in vitro results, mice were pretreated with hydro-cy3, mechanical wounds were generated in exteriorized colonic mucosa, and the hydro-cy3 fluorescence signal was detected by confocal microscopy. Of interest was the observation that a 15-minute exposure of IECs to the Ac2-26 peptide enhanced ROS generation in wounded colonic mucosa from WT mice (Figure 2D). Furthermore, increased ROS was largely abrogated by the FPR1 inhibitor CsH, further supporting a role of FPR1 in mediating this cellular response. Interestingly, compared with the striking ROS generation in control mice, colonic epithelial cells in IEC-specific Nox1–null (Nox1–/–IEC) mice revealed minimal ROS generation that was not increased following treatment with Ac2-26 (Figure 2E). These Nox1–/–IEC mice were produced as shown in Supplemental Figure 4, A and B. To show that the oxidant production was specific to NOX1, we examined phagocytic ROS generation in wounded epithelium by testing Nox2–/– mice. As shown in Figure 2F, ROS generation was detected in colonic epithelial cells adjoining wounds of Nox2–/– mice to a level comparable to that in WT mice. These results highlight a novel role of intestinal epithelial NOX1 in mediating ROS generation in response to Ac2-26. Ac2-26 promotes oxidative inactivation of PTP-PEST and PTEN. Intracellular ROS signaling modulates a subset of regulatory proteins by rapid and reversible oxidation of redox-reactive cysteine residues that results in their catalytic inactivation (Figure 3A and refs. 37–40). Such regulatory proteins include phosphatases that modulate the phosphorylation status of focal adhesion proteins such as FAK and Pax, important in controlling cell...
ANXA1 regulates wound healing via FPR1 signaling in IECs and stimulates phosphorylation of focal adhesion proteins (FAK and Pax). (A) SK-CO15 monolayers were subjected to scratch wound assay in the presence of Ac2-26 peptide (3 μM). Wound widths were determined at 0 and 24 hours. Photomicrograph shows representative results for control (Ctl) and Ac2-26–treated cells. Scale bar: 200 μm. (B) SK-CO15 cells were also incubated with Ac2-26 and CsH (1 μM) or WRW4 (10 μM). The ANXA1 cleavage product Ac2-26 alone significantly enhanced wound closure (\*P < 0.0001). The increase in wound closure was inhibited in the presence of CsH (\#P < 0.0001) but not WRW4. The experiment was repeated 3 times, and results of 1 representative experiment done with 5 parallel samples are shown. (C) Endoscopic images of colonic mucosal wounds in mice (AnxA1−/− and control BALB/c) at days 2 and 4 after injury. Quantification of wound repair is shown in the graph (mean ± SEM, \*P = 0.023, n = 11 mice/group). (D) SK-CO15 cells were plated on ECL gel, and non-adherent cells were removed by washing at 1 hour after plating. Adhesion increased within 15 minutes of Ac2-26 exposure compared with non-stimulated cells (\*P < 0.0001). (E) Immunoblot of SK-CO15 cells revealed a significant increase in Pax phosphorylation (Y118, 2.4-fold) and FAK phosphorylation (Y861, 2.2-fold) in cells stimulated with Ac2-26 for 15 minutes compared with unstimulated cells (0.1% DMSO). Normalized signal intensity is indicated above the blots. (F) Laser confocal micrographs of Pax p-Y118 (white) or FAK p-Y861 (white) and F-actin (red) in migrating SK-CO15 cells with or without Ac2-26 (3 μM) for 15 minutes. Photomicrographs are representative of 3 independent experiments done in triplicate. Scale bars: 10 μm.
movement (41). Thus, to determine whether Ac2-26–induced ROS could influence IEC motility and therefore wound closure by a redox-dependent mechanism, we analyzed the oxidation of cysteine residues in candidate relevant phosphatases such as PTP-PEST, PTEN, and SHP2. ROS-induced oxidation of cysteine residues was determined using the thiol-reactive agent biotin-NH₂-maleimide (biotin-NM), which irreversibly alkylates thiol-anionic -SH groups of active redox-sensitive cysteines. Capture
of associated phosphatases by streptavidin precipitation and immunoblotting thus reflects the amount of active protein. As shown in Figure 3B, exposure of migrating cells to Ac2-26 (3 μM) for 15 minutes oxidized reactive cysteines in PTP-PEST and PTEN but not SHP2. H2O2 (15 μM) was used as a positive control to demonstrate global nonspecific cysteine oxidation and, as expected, induced loss of maleimide modification of these phosphatases. These observations support a role for ROS-induced oxidative inactivation of PTP-PEST and PTEN that, in turn, increases phosphorylation and activation of downstream focal adhesion proteins, promoting IEC migration (42, 43).

Ac2-26–induced FPR1 stimulation promotes formation of a Rac1 signaling complex linked to ROS generation. We next sought to determine the signaling events that regulate ROS production downstream of Ac2-26. Given the relationship of the GTPase Rac and NOX2/ROS in leukocytes, we next examined Ac2-26 promotion of ROS generation by activation of Rac1 GTPase in epithelial cells. Ac2-26–induced activation of epithelial Rac1 was followed by measurement of the specific interaction of Rac1-GTP with its effector protein p21-activated kinase (PAK) (44, 45). Ac2-26 induced a robust and rapid activation of Rac1 within 15 minutes of peptide exposure (3-fold increase, Figure 3C) that was inhib-

Figure 3
Ac2-26 oxidizes PTP-PEST and PTEN and activates Rac1-GTPases. (A) ROS oxidize thiols in redox-sensitive phosphatases (PTPs). Maleimide groups react efficiently and specifically with reduced sulfhydryls (R-SH) of PTPs to form stable thioester bonds but do not react and bind R-SOH oxidized sulfenic acid (thioester) forms. (B) Cell were treated with vehicle, H2O2 (15 μM), or Ac2-26 (3 μM) for 15 minutes and subjected to labeling with biotin-NM. Biotinylated proteins were precipitated with SA beads and subjected to immunoblot analysis using PTEN, PTP-PEST, and SHP2 antibodies. β-Actin was used as a loading control. Immunoblots presented are representative of 3 independent experiments. Normalized signal intensity is indicated above the blots. (C) SK-CO15 cells were incubated for 30 minutes at room temperature with 100 μM GTPγS, vehicle, or Ac2-26 peptide for 15 minutes. Active Rac1 (Rac1-GTP) was pulled down using agarose bead–conjugated GST-PAK-RBD. Total (Rac1) and active Rac1 (Rac1-GTP) were analyzed by immunoblot. Immunoblots are representative of 3 independent experiments. (D) Active Rac1 pull-down samples were subjected to immunoblot analysis with antibodies against Vav2, p120, and NOX1. Immunoblots are representative of 3 independent experiments. (E) ROS generation was analyzed in SK-CO15 cells, treated with hydro-Cy3 dye, by confocal microscopy. Cells were incubated with vehicle, Ac2-26 (3 μM), or Ac2-26 plus NSC23766. Micrographs are representative of 3 independent experiments. Scale bar: 20 μm. (F) SK-CO15 cells were transfected with siRNA targeting p120 catenin. Three days after siRNA transfection, cells were treated with Ac2-26 for 15 minutes, and ROS generation was detected. Confocal micrographs are representative of 3 independent experiments. Scale bar: 20 μm. Summarized data for hydro-Cy3 fluorescence intensity are presented in the graphs (mean ± SEM,* P < 0.05 vs control, # P < 0.05 vs Ac2-26, n = 3).
Ac2-26 enhances Src kinase activity. Since we observed that p120 mediates Ac2-26–induced ROS generation, further experiments were performed to identify mechanisms of p120 activation and ROS generation. Previous reports demonstrated that p120 was first identified as an Src substrate (50). Additionally, Src has been reported to increase NOX1-dependent ROS generation (51). We therefore investigated whether Src activation mediates Ac2-26–induced ROS generation by analyzing Src phosphorylation at the Y418 residue (52). Indeed, immunoblot analysis revealed a significant increase in Ac2-26–induced Src phosphorylation (8-fold increase compared with unstimulated cells). This effect was abrogated by CsH (Figure 4A), while the total Src protein remained unchanged. To test the functional relevance of Src activation in IEC ROS generation following Ac2-26 treatment, we incubated IECs with Ac2-26 in the presence of pharmacologic Src inhibitors (PP2 and AZM475271) (53–55). As shown in Figure 4B, a significant decrease in ROS generation was observed following treatment of cells with the Src inhibitors. These findings suggest a novel role for Src kinase in mediating FPR1-induced ROS generation following stimulation of epithelial cells with Ac2-26.

**In vivo administration of ANXA1 promotes recovery of colonic mucosal wounds.** Since our in vitro data suggested that ANXA1 facilitates epithelial wound closure, thereby serving as a pro-resolution factor, we analyzed the influence of ANXA1 administration on colonic mucosal wound healing in vivo using recombinant ANXA1 protein. After generating mucosal wounds with mouse colonoscopy, we investigated wound closure following ANXA1 i.p. systemic administration versus PBS delivery (control) in WT and Nox1+/− and Nox1−/− mice. Consistent with the in vitro wound closure results, ANXA1 administration promoted mucosal wound repair (64.57% wound closure in ANXA1-treated mice vs. 40.69% wound closure in WT control mice, P < 0.001). Interestingly, ANXA1 did not augment wound healing in the absence of NOX1, and recovery in NOX1-deficient mice treated with PBS was indistinguishable from that in WT mice (Figure 5A). To further confirm our results, we additionally analyzed ANXA1 pro-resolution activity in mice with DSS-induced colonic mucosal injury. Analysis of

**Figure 4**

Ac2-26 peptide activates Src kinase. (A) Immunoblots of phospho-Src (Src p-Y418) and total Src (c-Src) expression in SK-CO15 cells stimulated with control (0.1% DMSO) and Ac2-26 (3 μM) for 15 minutes. Immunoblots are representative of 3 independent experiments. Normalized signal intensity is indicated above the blots. (B) Confocal images of ROS-sensitive hydro-Cy3 in SK-CO15 cells treated with vehicle, Ac2-26 (3 μM), or Ac2-26 (3 μM) after preincubation with PP2 and AZM. Confocal micrographs are representative of 4 independent experiments. Scale bar: 20 μm. Summarized data for hydro-Cy3 fluorescence intensity are presented in the graph (mean ± SEM, #P < 0.05 vs. control, ∗P < 0.05 vs. Ac2-26 n = 4).
disease activity index revealed that ANXA1 administration (5 μg, twice per day) improved clinical recovery from colitis (P < 0.001, Figure 5B). Interestingly, ANXA1 administration was associated with reduced mucosal ulceration (Figure 5C and Supplemental Figure 5B). Even a lower dose of ANXA1 (1 μg, twice per day) afforded significant mucosal healing in WT mice (Supplemental Figure 6A). To further analyze the role of NOX1 in mediating the pro-resolution activity of ANXA1 during mucosal repair following colitis, we examined the effect of ANXA1 administration in Nox1–/–IEC mice. Figure 5, B and C, show that ANXA1 administration did not improve the clinical outcome of mice recovering from DSS-induced colitis in the absence of epithelial NOX1 enzyme. Since ANXA1 promoted colonic mucosal wound recovery in vivo, we analyzed ANXA1 expression in the vicinity of mucosal wounds. Mouse colonic wounds recovering from biopsy-induced injury were harvested and ANXA1 immunolocalized by confocal microscopy (Figure 6A, green). At the time of injury (day 0), baseline ANXA1 expression was observed in the intestinal epithelium and in scattered mucosal inflammatory cells. However, the expression of ANXA1 in the epithelium and in infiltrating leukocytes during wound recovery was markedly increased (days 1 and 6 after injury). Given these observations in mice, we assessed ANXA1 expression in human intestinal mucosa of patients with ulcerative colitis (UC). As shown in Figure 6B, ANXA1 expression increased in the intestinal epithelium and infiltrating leukocytes in the injured mucosa of individuals with UC compared with normal intestinal mucosa. These findings are consistent with a recent study that reported increased ANXA1 receptor FPR2 expression in IBD patients (56).

Inflammation is characteristic of IBD, and proinflammatory NF-κB signaling is reflective of mucosal injury (57, 58). Recently, Ouyang et al. showed that MC-12, an ANXA1-based peptide exerts protective effects in experimental colitis by inhibiting the NF-κB pathway (59). Since the extent of p65 translocation into the nucleus qualitatively reveals NF-κB activation, we analyzed p65 localization in human IECs by immunofluorescence labeling and confocal microscopy. Ac2-26 inhibited p65 nuclear translocation induced by a combination of cytokines, TNF-α and IFN-γ (Supplemental Figure 7). Furthermore, to mechanistically demonstrate that ROS production is important in Ac2-26 inhibitory effects, we preincubated IECs with the NOX1 inhibitor DPI to block ROS generation. Ac2-26 failed to inhibit p65 nuclear translocation under these conditions. Taken together, these results suggest a role of endogenous ANXA1 and its mimetic peptide Ac2-26 in promoting epithelial barrier recovery via inhibition of proinflammatory events regulated by ROS generation.
Discussion
Mucosal inflammation compromises the epithelial barrier, resulting in exposure of systemic tissues to luminal bacterial products and antigens. In response, the epithelium has evolved a remarkable capacity to efficiently reseal the barrier defects. Such important reparative responses are modulated by mucosal mediators, such as anti-inflammatory protein ANXA1 (60–63). The beneficial effects of ANXA1 are exerted by a unique N-terminal peptide that is released by proteolysis from the full-length protein (2, 13, 14, 64). The importance of the N-terminal domain in mediating anti-inflammatory activity is further supported by studies wherein deletion of the N terminus induced inactivation of the protein, while use of synthetic N terminus peptides exerted pharmacologic activity (65, 66). Our in vivo studies demonstrated increased ANXA1 expression in the injured intestinal epithelium as well as in infiltrating leukocytes. These findings suggest that increased ANXA1 derived from distinct cell populations within wounds exerts paracrine/autocrine effects on epithelial FPR to facilitate wound closure and epithelial barrier recovery. Congruently, extravasated leukocytes synthesize ANXA1 (11, 12), which provides resolution signals to promote mucosal repair. In support of our experimental in vitro and in vivo observations in mice, we also observed increased ANXA1 protein in inflamed intestinal mucosa of patients with UC.

These findings are in keeping with a previous published study showing that ANXA1 was endogenously secreted in the colon of patients with UC (67).

ANXA1 is an endogenous ligand for FPR. Classically, FPR signaling during phagocyte response to bacterial products results in a high level of ROS production, the microbiocidal “oxidant burst.” In this report, we demonstrate a beneficial role of FPR signaling in mediating ANXA1-induced epithelial ROS generation that exerts a novel pro-resolution function in vivo. Our study demonstrating the importance of FPR signaling in promoting epithelial wound closure supports previous reports by Gronert et al. (68–70). These studies highlighted a critical role of another pro-resolving FPR2 ligand, LXA4, in facilitating recovery of corneal epithelial wounds. Topical treatment with LXA4 not only accelerated wound closure, but also attenuated chemokine release. Furthermore, LXA4-dependent protective effects were sex specific, as estradiol was able to downregulate LXA4 formation (68).

Therapeutic effects of ANXA1 on intestinal epithelial wound closure were observed both following biopsy of the colonic mucosa and in recovery from DSS-induced colitis. Our studies provide a detailed understanding of the mechanism by which ANXA1-dependent ROS generation promotes wound repair. The novelty of our work is the identification of a central role of intestinal epithelial FPR and NOX1 in mediating the downstream beneficial effects of ANXA1 in facilitating mucosal repair. AnxA1–/– and newly generated Nox1–/–IEC mice were instrumental in demonstrating the beneficial effects and signaling pathways by which ANXA1 promotes mucosal barrier recovery. ANXA1 administration in Nox1–/–IEC mice failed to have pro-resolution effects on wound closure as observed in WT mice. Additionally, delayed intestinal mucosal wound healing was observed in AnxA1–/– mice. Analysis of the signaling pathway revealed a role of Src and Vav2 in mediating NOX1-dependent ROS generation induced by ANXA1. The downstream beneficial effects of NOX1-dependent ROS signaling in turn are mediated by oxidative inactivation of key regulatory phosphatases that regulate actin cytoskeletal and focal adhesion dynamics (71–73). We have recently demonstrated oxidative inactivation of low-molecular-weight protein tyrosine phosphatase (LMW-PTP) that was induced by bacterially stimulated ROS to promote wound closure (34). Consistent with these studies, we report here that PTEN and PTP-PEST are rapidly and transiently inactivated by ROS in cells treated with Ac2-26. Additionally, the link between inactivation of these phosphatases and focal adhesion protein dynamics is sup-

Figure 6
Mucosal ANXA1 expression is increased in injured murine and human colonic tissue. (A) Representative images of colonic mucosa from WT mice 0, 1, and 6 days after biopsy-induced injury. Frozen sections were stained with antibodies against ANXA1 (green), F-actin (phalloidin, red), and nuclei (TO-PRO-3, blue). Scale bar: 100 μm. The bottom row shows photomicrographs of colonic mucosa wounds on days 0, 1, and 6; n = 5 mice/group. (B) Sections of human colonic tissue from healthy control and UC patients were stained with ANXA1 (green) and F-actin (red). Scale bars: 20 μm.
ported by previous studies demonstrating that PTP-PEST and PTEN can directly regulate the tyrosine phosphorylation of FAK and Pax and therefore influence cell motility (42, 43).

In the context of resolution of mucosal inflammation, epithelial repair represents an important final event after modulation of immune cell recruitment and clearance of extravasated cells. ANXA1 has been shown to dampen excessive immune cell trafficking by distinct mechanisms that include inhibition of neutrophil influx (11, 74) and promotion of neutrophil apoptosis at the site of resolving inflammation (75, 76). Intact ANXA1 and its derived peptides have been shown to mediate suppression of the proinflammatory NF-κB pathway (9, 77, 78). Recently, Ouyang et al. showed that MC-12, an ANXA1-based peptide, also inhibits NF-κB, thereby exerting a protective effect in experimental colitis (59). Similarly, we show that the ANXA1 mimetic peptide Ac2-26 can inhibit NF-κB in a redox-dependent manner (Supplemental Figure 7). These findings are consistent with our past observations that ROS induced by exogenous agents serves to suppress NF-κB activation by the same biochemical mechanism shown herein: namely, oxidative inactivation of catalytic cysteines in the active site of enzymes involved in processing ubiquitin-like proteins necessary for NF-κB activation (79, 80). In the context of wound injury, the ROS-mediated activation of pro-restitution enzymes such as FAK that stimulate epithelial cell migration would be effectively linked and coordinated with blockade of NF-κB and consequent cellular inflammation that would impede optimal wound healing.

In summary, the current study has uncovered a novel FPR1/NOX1-dependent ROS signaling pathway in IECs and has identified key regulatory components that mediate tissue repair activity of ANXA1 (Figure 7). This cascade involves key signaling proteins including Src, p120, Vav2, Rac1, and Nox1 and culminates in ROS generation, oxidation/inactivation of phosphatases, PTP-PEST, and PTEN, which in turn promotes activation of focal cell matrix adhesion proteins, cell motility, and ultimately wound closure. Taken together, the in vitro and in vivo studies (epithelial wound repair/recovery) demonstrate an influence of ANXA1 in the “final act” during resolution of inflammation, which requires efficient tissue repair and restoration of mucosal homeostasis. Last, these studies suggest that ANXA1 could potentially be used as a therapeutic agent to facilitate wound repair and barrier recovery in the intestine.

Methods
Supplemental Methods are available online with this article; doi:10.1172/JCI65831DS1.

Mice. WT female BALB/c mice and Nox2-null mice were purchased from the Jackson Laboratory. AnxA1−/− mice were a gift from R.J. Flower (Barts and The London School of Medicine, London, United Kingdom) (81). Nox1−/− mice were generated as described in Supplemental Figure 3. Animals were housed under a standard day/night cycle, with free access to food and water.

Antibodies and reagents. Primary antibodies to SHP-2, PTP-PEST, Pax p-Y118, and Vav2 were purchased from Cell Signaling Technology; p120, Rac1, p65, and FAK from BD Biosciences; FAK p-Y861 from Calbiochem; PTEN from Abcam; Src (N-terminal region) from ECM Biosciences; Src
p-Y418 from Millipore; and β-actin and ANXA1 from Invitrogen. Secondary antibodies for Western blot analysis were obtained from Jackson ImmunoResearch Laboratories Inc. The chemical compound F2L was purchased from Phoenix Pharmaceuticals; NCS23766 was obtained from EMD; NAC, H2O2, and biotin-NM from Sigma-Aldrich; ECL gel from Invitrogen; peptide Ac2-26 (acyetyl-AMVSEFLKQAWFIENEEQEYVVQTVK), MMK1, DP1, WRW4, PP2, and AZM475271 from Tocris; rotenone from Ultra Scientific; Boc2 from MP Biomedicals; PTx from Calbiochem; CsH from Enzo Life Sciences; and Rac-Assay reagent from Millipore. Hydro-Cy3 dye was synthesized in our laboratory.

**ANXA1 recombinant protein purification.** cDNA of human ANXA1 carrying a cleavable N-terminal poly-His tag was expressed in E. coli. Recombinant protein was purified on IMAC (GE Healthcare), and the poly-His tag was subsequently removed. Purity of recombinant ANXA1 was confirmed by SDS-PAGE and the 4800 MALDI-TOF/TOF (82) (Applied Biosystems), revealing a 38.6-kDa protein that was >95% pure.

**In vivo ANXA1 treatment.** Intraperitoneal injections of 1 or 5 μg ANXA1 in 100 μl PBS twice a day were performed. This dosing schedule was chosen based on published literature (65, 83, 84).

**Cell lines and culture conditions.** Human IECs (SK-CO15) were grown in high-glucose (4.5 g/liter) Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum, 100 U/ml penicillin, 100 μg/ml streptomycin, 15 mM HEPES (pH 7.4), 2 mM l-glutamine, and 1% non-essential amino acids, as previously described (85, 86).

**Immunoblot.** Epithelial cell monolayers were harvested in RIPA lysis buffer (150 mM NaCl, 1% NP-40, 0.5% deoxycholic acid, 0.1% SDS, 50 mM Tris [pH 8.0]) containing protease and phosphatase inhibitors (Sigma-Aldrich) and sonicated, and insoluble material was removed by centrifugation (16,000 g/10 min/4°C). Protein concentration was determined with a BCA assay, and samples were boiled in SDS buffer. Equal amounts of protein were separated by SDS-PAGE and transferred onto nitrocellulose membranes. Membranes were blocked for 1 hour with 3% wt/vol BSA in Tris-buffered saline containing 0.1% vol/vol Tween-20 and incubated with primary antibodies in blocking buffer overnight at 4°C, followed by 1-hour secondary antibody incubation. Densitometer analysis was performed using the ImageJ analysis program (NIH).

**Transfection of siRNA.** The p120 siRNA sequence pair (5′-GCTAUGAUGAC-CUGGAAUAU and 5′-UAUCUCUGAUAUCAG) was purchased from Sigma-Aldrich (87 SASI_Hs02_00317795) and used for transient knockdown of p120. Transient transfections were performed with LipofectAMINE 2000 (Invitrogen) according to the manufacturer’s instructions.

**Cell adhesion assays.** 96-well plates were incubated with ECM gel (5 μg/ml) overnight at 37°C. 5 × 10^4 cells were labeled with bis-carboxymethylcarboxyfluorescein (BCECF) and added to the wells. Cells were allowed to adhere for 2 hours at 37°C, and non-adherent cells were removed by washing the plates 3 times. Absorbance of adherent cells was measured at 488 nm in a microtiter plate reader (Multiskan plus version 2.03, Labsystems).

**Wound healing assay.** Cell migration was assessed using a scratch wound healing assay as previously published (87).

**Intracellular ROS generation experiments.** ROS production was visualized by using a stable and nontoxic red-oxide sensitive hydroxycyanine dye, hydro-Cy3 (88). Epithelial cells treated with Ac2-26 for the indicated times were incubated with 15 μM hydro-Cy3 for 30 minutes at 37°C. Epithelial cells were pretreated with NAC (20 mM), DPI (10 μM), rotenone (10 μM), PTx (1 μg/ml), CsH (1 μM) or Boc2 (1 μM), PP2 (10 μM), and NCS23766 (50 μM) 30 minutes prior to Ac2-26 treatment. ROS was detected by confocal laser scanning microscopy (Zeiss LSM 510) at x40 magnification. Quantification of fluorescence intensity of ROS was determined using ImageJ software. For in vivo ROS measurements, 0.1 ml PBS containing hydro-Cy3 (40 μM) was intrarectally administered with flexible no. 4 catheters inserted 3–4 cm into the distal colon of a mouse. After 30 minutes of dye administration, the colon was exteriorized, epithelial tissue was wounded, and HBSS (control) or Ac2-26 was added to the tissue for 15 minutes; in the same experiments, some mice were preincubated with CsH for 30 minutes before Ac2-26 administration. Mice were sacrificed; colon tissue was fixed in PFA 3.7%, sectioned, and mounted with Vectashield; and fluorescence was analyzed by confocal microscopy.

**Analysis of protein oxidation.** Phosphatase oxidation was monitored by labeling with the thiol-modifying reagent biotin-NM. Cells were treated with H2O2 (15 μM) or Ac2-26 (3 μM) biotinylated by incubation for 30 minutes at 50°C with a solution containing 50 mM HEPES-NaOH, pH 7.5, 1 mM EDTA, 2% SDS, and protease inhibitors with 12 μM biotin-NM. The reaction was stopped by the addition of DTT to a final concentration of 100 mM, and biotinylated proteins were then precipitated by incubation overnight at 4°C with 50 μl streptavidin-agarose (SA) beads. The beads were washed 5 times with a solution containing 20 mM HEPES-NaOH (pH 7.7), 200 mM NaCl, 1 mM EDTA, and 0.5% SDS. Biotinylated proteins were released from the beads by boiling in SD/SDS PAGE sample buffer and subjected to immunoblot analysis.

**Rac1 activation assay.** SK-CO15 cells were washed in cooled TBS before lysis in supplied magnesium lysis buffer (MLB) containing protease inhibitors. Lysates were normalized for protein concentrations using a bicinchoninic acid assay (Pierce) and incubated with recombinant PAK1-GST coupled to agarose beads (45 minutes, at 4°C with rotation). Beads were washed with MLB and resuspended in SDS sample buffer for immunoblot analysis.

**Colonoscopy in live mice.** Mice were anesthetized by i.p. injection of a ketamine (100 mg/kg)/xylazine (10 mg/kg) solution. To create intestinal mucosal wounds and monitor wound closure, we used a high-resolution colonoscopy system equipped with biopsy forceps (89, 90). This system consisted of a miniature rigid endoscope (1.9-mm outer diameter), a xenon light source, a triple-chip high-resolution CCD camera, and a 3 Fr operating sheath. Endoscopic procedures were viewed with high-resolution (1,024 x 768 pixels) images on a flat-panel color monitor. Wound size averaged approximately 1 mm², which is equivalent to removal of approximately 250–300 crypts (91). In each experiment, 10–15 lesions from 5–6 mice per group were examined (92).

**Immunofluorescence microscopy.** Cells grown on coverslips were fixed with 3.7% wt/vol PFA for 15 minutes, followed by 0.5% vol/vol Triton X-100 for 5 minutes. Tissue sections were fixed in 100% vol/vol ethanol. Samples were then blocked with 3% wt/vol BSA for 1 hour and incubated with primary antibody overnight at 4°C, washed, and incubated for 1 hour with fluorophore-labeled secondary antibodies, then mounted in p-phenylene. Images were taken on an LSM 510 confocal microscope (Zeiss) with Plan-NEOFLUAR ×100/1.3 oil, ×40/1.3 oil, and ×20/0.5 dry objectives, with software supplied by the vendor.

**Induction of colitis.** 3% (wt/vol) DSS (molecular mass, 36–50 kDa; MP Biomedicals) was dissolved in purified water and orally administered to mice as previously described (82). Mice were allowed free access to food and drinking water containing 3% DSS from day 0 until day 7, and DSS was withdrawn to allow recovery from colitis for an additional 6 days. Mice were sacrificed on day 13. Daily clinical assessment of DSS-treated animals included evaluation of stool consistency, detection of blood in stool, and body weight loss measurements. An individual score (ranging from 0 to 4) was attributed for each one of these parameters, and a disease activity index ranging from 0 to 4 was calculated by combining all three scores (82).

**Statistics.** Quantitative data are expressed as mean ± SEM for each treatment group. Statistical comparisons were performed by either 2-tailed Student’s t test or ANOVA with Tukey’s multiple comparison post-test (GraphPad Prism; GraphPad Software). P values less than 0.05 were considered significant.
Study approval. All procedures using animals were reviewed and approved by the Emory University IACUC and were performed according to NIH criteria.

Acknowledgments

The authors would like to thank R.J. Flower (Barts and The London School of Medicine) for providing the AnxA1 mouse; Attila E. Farkas and Al Jesaitis for critically reviewing the manuscript; and Courtney S. Arditia for technical help. This work was supported by R01DK089763 and R01DK055679 to A. Nusrat; R01AI64642 to A. S. Neish; DK061379, DK072564, and DK079392 to C.A. Parkos; R01HL096796-3 to N. Murthy; and grants from the William Harvey Research Foundation to M. Perretti, the German Research Foundation (Deutsche Forschungsgemeinschaft, NE1834/1-1) to P.-A. Neumann, and the Emory Digestive Diseases Research Development Center Core Grant (DK064399).

Received for publication July 16, 2012, and accepted in revised form October 18, 2012.

Address correspondence to: Asma Nusrat, Whitehead Biomedical Research Building, Room 105M, 615 Michael Street, Atlanta, Georgia 30322, USA. Phone: 404.727.8543; Fax: 404.727.8538; E-mail: anusrat@emory.edu. Or to: Andrew S. Neish, Whitehead Biomedical Research Building, Room 105F, 615 Michael Street, Atlanta, Georgia 30322, USA. Phone: 404.727.8543; Fax: 404.727.8538; E-mail: aenish@emory.edu.


